ERK1/2 promoted proliferation and inhibited apoptosis of human cervical cancer cells and regulated the expression of c-Fos and c-Jun proteins

Risk Factors for Cervical Cancer in Rural Areas of Wuhan China: a Matched Case-control Study

(2014) Bin Zhang et al.   Asian Pacific Journal of Cancer Prevention

Insulin Promotes Proliferation and Migration of Breast Cancer Cells through the Extracellular Regulated Kinase Pathway

(2014) Feng Pan et al.   Asian Pacific Journal of Cancer Prevention

ERKs in Cancer: Friends or Foes?

(2014) Xavier Deschênes-Simard et al.   CANCER RESEARCH

MEK1/2 inhibitors in the treatment of gynecologic malignancies

(2014) Caela R. Miller et al.   GYNECOLOGIC ONCOLOGY

Thymoquinone-induced conformational changes of PAK1 interrupt prosurvival MEK-ERK signaling in colorectal cancer

(2014) Chirine El-Baba et al.   Molecular Cancer

Axl Kinase as a Key Target for Oncology: Focus on Small Molecule Inhibitors

(2014) C. Feneyrolles et al.   MOLECULAR CANCER THERAPEUTICS

Overexpression of HepaCAM inhibits cell viability and motility through suppressing nucleus translocation of androgen receptor and ERK signaling in prostate cancer

(2014) Xuedong Song et al.   PROSTATE

Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors

(2014) Elizabeth Smyth et al.   OncoTargets and Therapy

Small molecule inhibitors of the hedgehog signaling pathway for the treatment of cancer

(2012) Jeong In Yun et al.   ARCHIVES OF PHARMACAL RESEARCH

Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy

(2012) Libero Santarpia et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

ERK1/2 MAP kinases: Structure, function, and regulation

(2012) Robert Roskoski   PHARMACOLOGICAL RESEARCH

Claudin-7 inhibits human lung cancer cell migration and invasion through ERK/MAPK signaling pathway

(2011) Zhe Lu et al.   EXPERIMENTAL CELL RESEARCH

Phenethyl isothiocyanate sensitizes human cervical cancer cells to apoptosis induced by cisplatin

(2011) Xiantao Wang et al.   MOLECULAR NUTRITION & FOOD RESEARCH

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers

(2010) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH